ProCE Banner Activity

Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

Podcast Episodes
In this podcast episode, listen to Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on the evolving role of BTK inhibitors in CLL, including sequencing, combinations, and novel agents.

Released: November 09, 2022

Expiration: November 08, 2023

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.
ProCE Banner

Supporters

This CE activity is supported through an educational grant from

AstraZeneca

BeiGene

Lilly

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Farrukh T. Awan, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Dava Oncology, Epizyme, Genentech, Gilead Sciences, Incyte, Janssen, Johnson & Johnson, Karyopharm, Kite, MEI Pharma, Merck, Pharmacyclics, Verastem.

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD: consultant/advisor: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Pharmacyclics; institutional researcher: AbbVie, AstraZeneca, BeiGene, Genentech, Loxo/Lilly, MingSight, Octapharma, Oncternal, TG Therapeutics.